Olutasidenib
Olutasidenib Phase 1/2 (glioma cohort)
Rigel · Phase 1/2 · Completed · Enrollment 93
| Arm | Reported safety |
|---|---|
| Olutasidenib 150 mg BID | grade 3 to 4 ALT increase: 12%grade 3 to 4 AST increase: 12% |
A count stays a count. This page does not turn a count into a percent.